急性髓系白血病靶向治疗进展

Advances of Targeted Therapy for Acute Myeloid Leukemia--Review

急性髓系白血病(AML)临床表现具有高度异质性,预后差,治疗以传统化疗为主。近年来,随着二代测序技术的深入发展,AML的治疗逐渐向分子生物学和免疫表型方向的精准靶向治疗发展,各种小分子抑制剂、免疫靶向药物等的问世为不能耐受强化疗和复发难治AML患者带来了希望。相较于传统化疗,靶向治疗具有疗效显著、副作用少等优点,现就AML靶向药物治疗最新研究进展作一综述。

Acute myeloid leukemia(AML)has highly heterogeneous clinical manifestations and poor prognosis,and traditional chemotherapy is the main treatment.In recent years,with the in-depth development of next-generation sequencing technology,the treatment of AML is gradually exploring the precise targeted therapy in the direction of molecular biology and immunophenotype.The advent of various small-molecule inhibitors and immune-targeted drugs has brought hope to patients who cannot tolerate intensive chemotherapy or with relapsed/refractory AML.Compared with traditional chemotherapy,targeted therapy has the advantages of significant curative effect and fewer adverse effects.This article reviews the latest research progress of targeted drug therapy for AML.